Stephane Chatonsky, MBA, GAICD is a highly experienced non-executive director and board chair, with deep expertise in finance and strategy within the technology and healthcare space. With over 25 years of international experience across Australia, Asia and Europe, he has worked in investment banking with Lazard Freres and Macquarie Bank, strategy consulting at McKinsey, and in venture capital and private equity funds. Stephane currently serves as a non-executive director at Cerulea Clinical Trials; Genetic Signatures (ASX: GSS); Drop Bio Health, and Brainmates. He also serves as Chair at The CEO Institute, Honorary Fellow at Macquarie University, Adjunct Professor at the University of NSW, an expert-in-residence at Cicada Innovations and as an Expert Witness to the Federal Court of Australia.